Fluoroquinolones were originally developed for the Gram-negative aerobic spectrum, but the newer generation agents are also highly effective against some Gram-positive pathogens and cause few adverse effects. Owing to these characteristics, fluoroquinolones are often used in first line therapy in small animal practice. However, their widespread use has raised concern over emerging bacterial resistance. In this study we evaluated the in vitro efficacy of two fluoroquinolones, marbofloxacin and enrofloxacin, on field strains isolated from clinical infections between 2002 and 2005. Our data show that most of the isolates are still sensitive to both antimicrobials and marbofloxacin was more effective than enrofloxacin, especially against P. aeruginosa and beta-Streptococci (P < 0.01). beta-Streptococci demonstrated the greatest resistance to the two study drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/0036-7281.149.6.265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of and .
Molecules
November 2024
Department of Clinical Microbiology, Royal University Hospital and Saskatchewan Health Authority, Saskatoon, SK S7N 0W8, Canada.
Pradofloxacin is a dual targeting, bactericidal fluoroquinolone recently approved for treating bacteria causing swine respiratory disease. Currently, an abundance of in vitro data does not exist for pradofloxacin. We determined the minimum inhibitory concentration (MIC) and mutant prevention concentrations (MPC) of pradofloxacin compared to ceftiofur, enrofloxacin, florfenicol, marbofloxacin, tildipirosin, tilmicosin and tulathromycin against swine isolates of and .
View Article and Find Full Text PDFFungal dysbiosis following antibacterial monotherapy in canine otitis externa.
J Small Anim Pract
November 2024
Department of Clinical Sciences and Services, University of London, Hatfield, UK.
Article Synopsis
- The study aimed to investigate whether treating refractory bacterial otitis in dogs with specific topical antibiotics leads to an increase in yeast overgrowth, particularly Malassezia.
- Twenty-nine dogs were treated with either fluoroquinolone or a combination of piperacillin and tazobactam, and ear swabs were taken to measure bacterial and yeast levels before and after treatment.
- Results showed a significant reduction in bacterial infections after treatment, but a notable increase in yeast (especially in dogs treated with piperacillin/tazobactam), highlighting the importance of monitoring for yeast overgrowth during antibacterial treatment.
Antimicrobial Susceptibility of Canine and Feline Urinary Tract Infection Pathogens Isolated from Animals with Clinical Signs in European Veterinary Practices during the Period 2013-2018.
Antibiotics (Basel)
May 2024
CEESA ComPath Study Group, 1050 Brussels, Belgium.
Bacterial urinary tract infections (UTIs) occur frequently in companion animals and are often treated with antibiotics. However, antimicrobial resistance can severely hamper treatment success. Therefore, antimicrobial susceptibility monitoring is key.
View Article and Find Full Text PDFComparative In Vitro Killing by Pradofloxacin in Comparison to Ceftiofur, Enrofloxacin, Florfenicol, Marbofloxacin, Tildipirosin, Tilmicosin and Tulathromycin against Bovine Respiratory Bacterial Pathogens.
Microorganisms
May 2024
Department of Clinical Microbiology, Royal University Hospital and Saskatchewan Health Authority, Saskatoon, SK S7N 0W8, Canada.
Pradofloxacin is the newest of the veterinary fluoroquinolones to be approved for use in animals-initially companion animals and most recently food animals. It has a broad spectrum of in vitro activity, working actively against Gram-positive/negative, atypical and some anaerobic microorganisms. It simultaneously targets DNA gyrase (topoisomerase type II) and topoisomerase type IV, suggesting a lower propensity to select for antimicrobial resistance.
View Article and Find Full Text PDFComparative Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and Seven Other Antimicrobial Agents Tested against Bovine Isolates of and .
Pathogens
May 2024
Department of Clinical Microbiology, Royal University Hospital and Saskatchewan Health Authority, Saskatoon, SK S7N 0W8, Canada.
Article Synopsis
- Pradofloxacin is a recently approved fluoroquinolone antibiotic that targets multiple sites, specifically for use in food animals.
- It has been evaluated alongside other antibiotics (ceftiofur, enrofloxacin, etc.) to determine its Minimum Inhibitory Concentration (MIC) and Mutant Prevention Concentration (MPC) values, showing strong efficacy against certain bacterial strains with low resistance potential.
- The drug's pharmacokinetic properties suggest that it remains effective in preventing resistance for an extended period (over 12-16 hours), making it a promising option for treating bovine respiratory diseases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!